Molina Healthcare, Inc. (MOH) Stock Price & Analysis
Molina Healthcare, Inc. (MOH) fell 1.37% to USD 197.55 as of July 25, 2026 at 01:47 UTC, according to Nexqual real-time market data.
MOH last closed at USD 200.29; the session ranged USD 193.49–200.26 on volume of 1,182,588 shares. Market capitalization is $10.31B, with a 52-week range of USD 121.06–244.89 (NYQ). Source: Nexqual, July 25, 2026 at 01:47 UTC.
Key Statistics (as of July 25, 2026 at 01:47 UTC)
| Price | USD 197.55 |
|---|---|
| Change | ▼ 1.37% (down) |
| Previous Close | USD 200.29 |
| Open | USD 198.33 |
| Day Range | USD 193.49 – 200.26 |
| 52-Week Range | USD 121.06 – 244.89 |
| Volume | 1,182,588 shares |
| Market Cap | $10.31B |
| Exchange | NYQ |
Technical Analysis (MOH)
Nexqual's technical model rates MOH "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:47 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 35.86 (neutral) |
| vs SMA50 | Below (USD 205.33) |
| MACD | 1.66 (positive) |
Analyst Ratings (MOH)
Wall Street analysts rate MOH "Hold" based on 17 analysts, with a mean price target of USD 210.06 (range USD 147–266), per Nexqual as of July 25, 2026 at 01:47 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 210.06 |
| High Target | USD 266 |
| Low Target | USD 147 |
| Buy / Hold / Sell | 3 / 15 / 1 |
Earnings (MOH)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 0.83 |
| Revenue Estimate | $10.88B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.51 vs est 1.4 ▲ beat |
| 2026-03-31 | USD 2.35 vs est 1.91 ▲ beat |
| 2025-12-31 | USD -2.75 vs est 0.33 ▼ miss |
| 2025-09-30 | USD 1.84 vs est 3.89 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financials & Fundamentals (MOH)
| Total Revenue | $42.47B |
|---|---|
| Revenue Growth (YoY) | -5.70% |
| Gross Margin | +8.43% |
| Operating Margin | +1.40% |
| Profit Margin | -0.02% |
| ROE | -0.16% |
| Debt / Equity | 94.77 |
| Current Ratio | 1.68 |
| Total Cash | $8.92B |
| Total Debt | $3.95B |
| Free Cash Flow | $700.25M |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financial Health Score (MOH)
Nexqual rates Molina Healthcare, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 01:47 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 8%, operating 1% |
| Balance Sheet | Mixed — $8.92B cash vs $3.95B debt, net cash position |
| Cash Flow | Mixed — FCF $700M, slim 1.5% margin |
| Efficiency | Critical — ROE -0%, ROA 1.2% |
Ownership (MOH)
| Insider Ownership | +1.42% |
|---|---|
| Institutional Ownership | +112.12% |
| Shares Outstanding | 52.20M |
| Float | 48.39M |
| Short % of Float | +7.35% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Leadership (MOH)
Molina Healthcare, Inc. is led by Joseph Michael Zubretsky (age 68), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:47 UTC.
| President, CEO & Director | Joseph Michael Zubretsky (age 68) |
|---|---|
| Senior EVP, CFO & Treasurer | Mark Lowell Keim (age 60) |
| Senior EVP & COO | James Edwin Woys (age 66) |
| Executive Vice President of Medicaid | Debra Jean Bacon (age 58) |
| Vice President of Compliance | Joann Zarza-Garrido |
Major Backers & Investors (MOH)
Notable institutional backers of Molina Healthcare, Inc. include Capital Group, FMR, LLC, AQR Capital Management, LLC, according to Nexqual as of July 25, 2026 at 01:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 7.66% |
| FMR, LLC | 6.15% |
| AQR Capital Management, LLC | 5.5% |
| Victory Capital Management Inc. | 3.97% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 2.89% |
| SmallCap World Fund Inc | 2.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.84% |
| BlackRock | 18.22% |
| State Street | 3.32% |
| Dimensional Fund Advisors | 2.68% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
From Molina Healthcare, Inc.'s Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- We have achieved a 90% re-procurement win rate for Medicaid requests for proposal ("RFP") representing $14 billion in retained revenue and an 80% new contract win rate worth $20 billion in premium, and we have completed acquisitions totaling more than $10 billion of revenue during this period. • The Plan.
- We believe our singular focus on government-sponsored healthcare enables us to identify and implement efficiencies that distinguish us as the low-cost, high-quality health plan of choice.
- Our provider networks are a key asset that provide us with a competitive unit cost position and quality service levels, which allows us to deliver the right health care, at the right time, in the right setting.
Partnerships
- Contracts We enter into MAPD and C-SNP contracts with CMS annually, and for D-SNP, HIDE, FIDE, CO D-SNP, and MMP (collectively, "dual-eligible programs"), we enter into contracts with CMS, in partnership with each state's department of health and human services.
- Pharmacy We outsource pharmacy benefit management services, including benefits design consultation, drug formulary management, claims processing, pharmacy network contracting, rebate processing and mail and specialty pharmacy fulfillment services, via our long-standing pharmacy benefit management ("PBM") agreement with CVS Caremark ("Caremark").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNC | Centene Corporation | USD 63.41 | ▼ 3.76% |
| HUM | Humana Inc. | USD 389.32 | ▼ 2.08% |
| ELV | Elevance Health, Inc. | USD 377.68 | ▼ 2.93% |
| UHS | Universal Health Services, Inc. | USD 155.75 | ▲ 4.29% |
| CI | The Cigna Group | USD 289.57 | ▲ 1.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:47 UTC. This page is informational and not investment advice.